Lung Cancer Clinical Trial
— ZEALOfficial title:
A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMAâ„¢) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC
Verified date | September 2023 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread. Clinical research has shown that drugs that inhibit vascular endothelial growth factor receptor (VEGFR) or epidermal growth factor receptor (EGFR) signalling can increase overall survival in patients with advanced non-small cell lung cancer (NSCLC). Preclinical studies have shown that vandetanib (ZD6474) is an inhibitor of both VEGFR and EGFR signalling. Giving vandetanib may therefore inhibit the growth of cancer cells by blocking their blood supply and by stopping them from dividing. This lung cancer study is to investigate if adding vandetanib to Alimta (pemetrexed) is more effective than Alimta (pemetrexed) alone.
Status | Completed |
Enrollment | 698 |
Est. completion date | February 14, 2023 |
Est. primary completion date | September 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Provision of informed consent - Female or male aged 18 years or above - Histologic or cytologic confirmation of locally advanced or metastatic NSCLC (stage IIIB or IV) on entry into study - Failure of 1st line anti-cancer therapy (either radiological documentation of disease progression or due to toxicity) or subsequent relapse of disease following 1st line therapy - WHO Performance status 0 - 2 - One or more measurable lesions at least 10 mm in the longest diameter (LD) by spiral CT scan or 20 mm with conventional techniques according to RECIST criteria. Previously irradiated lesions will not be considered measurable. - Life expectancy of 12 weeks or longer - Negative pregnancy test for women of childbearing potential only Exclusion Criteria: - Mixed small cell and non-small cell lung cancer histology - Patients have received 2nd-line or subsequent anti-cancer therapy - Prior treatment with pemetrexed - Prior treatment with VEGFR TKIs (previous treatment with bevacizumab [Avastin] is permitted) - Known or suspected brain metastases or spinal cord compression, unless treated at least 4 weeks before entry, and stable without steroid treatment for 10 days - The last radiation therapy within 4 weeks before the start of study therapy, not including local palliative radiation - The last dose of prior chemotherapy or other anti-cancer therapy is discontinued less than 3 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin, and suramin) - Major surgery within 4 weeks before entry, or incompletely healed surgical incision - Neutrophils <1.5 x 109/L or platelets <100 x 109/L - Serum bilirubin >1.5 x the upper limit of reference range (ULRR) - Creatinine clearance <50 ml/min calculated by either Cockcroft -Gault, 24 hours urine collection, EDTA scan or other validated methods - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 x ULRR in the absence of liver metastases, or > 5 x ULRR in the presence of liver metastases - Alkaline phosphatase (ALP) >2.5 x ULRR in the absence of liver metastases, or >5 x ULRR in the presence of liver metastases - Current active gastrointestinal disease that may affect the ability of the patient to absorb ZD6474 or tolerate diarrhoea - Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol - Any unresolved toxicity greater than CTCAE Grade 2 from previous anti-cancer therapy - Significant cardiovascular event (e.g., myocardial infarction, superior vena cava [SVC] syndrome), New York Heart Association [NYHA] classification of heart disease =2 within 3 months before entry, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia - History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded - Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age - QT prolongation with other medications that required discontinuation of that medication - Presence of left bundle branch block (LBBB) - QTc with Bazett's correction unmeasurable or = 480 msec on screening ECG (Note: If a patient has QTc interval =480 msec on screening ECG, the screen ECG may be repeated twice [at least 24 hours apart]. The average QTc from the three screening ECGs must be <480 msec in order for the patient to be eligible for the study) Patients who are receiving a drug that has a risk of QTc prolongation are eligible if QTc is <460 msec. - Potassium <4.0 mmol/L despite supplementation; serum calcium (or ionized or adjusted for albumin), or magnesium out of normal range despite supplementation - Women who are pregnant or breast-feeding - Any concomitant medications that may cause QTc prolongation or induce Torsades de Pointes or induce CYP3A4 function. Drugs that have a risk of QTc prolongation, that in the investigator's opinion cannot be discontinued, are allowed, but only of the QTc is <460 msec - Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 millimetre of mercury [mmHg] or diastolic blood pressure greater than 100 mmHg) - Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix and adequately treated basal cell or squamous cell carcinoma of the skin - Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment - Concomitant use of yellow fever vaccine or any live attenuated vaccines |
Country | Name | City | State |
---|---|---|---|
Argentina | Research Site | Avellaneda | |
Argentina | Research Site | Buenos Aires | |
Argentina | Research Site | Ciudad de Buenos Aires | |
Argentina | Research Site | Córdoba | |
Argentina | Research Site | La Plata | |
Argentina | Research Site | Ramos Mejía | |
Argentina | Research Site | Salta | |
Argentina | Research Site | Santa Fe | |
Australia | Research Site | Chermside | |
Australia | Research Site | Fitzroy | |
Australia | Research Site | Footscray | |
Australia | Research Site | Heidelberg | |
Australia | Research Site | Randwick | |
Australia | Research Site | St. Leonards | |
Australia | Research Site | Wodonga | |
Belgium | Research Site | Brussels (Woluwé-St-Lambert) | |
Belgium | Research Site | Leuven | |
Belgium | Research Site | Liège | |
Colombia | Research Site | Bogota | |
Colombia | Research Site | Medellín | |
Colombia | Research Site | Pereira | |
Colombia | Research Site | Valledupar | |
France | Research Site | Avignon Cedex 09 | |
France | Research Site | Lyon Cedex 04 | |
France | Research Site | Paris Cedex 15 | |
France | Research Site | Pontoise Cedex | |
France | Research Site | Strasbourg Cedex | |
Germany | Research Site | Hannover | |
Germany | Research Site | Karlsruhe | |
Germany | Research Site | Kassel | |
Germany | Research Site | Köln | |
Germany | Research Site | Leipzig | |
Greece | Research Site | N. Faliro | |
Greece | Research Site | Patras | |
Greece | Research Site | Thessaloniki | |
Hong Kong | Research Site | Hong Kong | |
India | Research Site | Ahmedabad | |
India | Research Site | Vellore | |
Israel | Research Site | Beer-Sheeva | |
Israel | Research Site | Haifa | |
Israel | Research Site | Jerusalem | |
Israel | Research Site | Kfar Saba | |
Israel | Research Site | Petach-Tikva | |
Israel | Research Site | Safed | |
Israel | Research Site | Tel-Hashomer | |
Israel | Research Site | Zerifin | |
Italy | Research Site | Genova | |
Italy | Research Site | Milano | |
Italy | Research Site | Orbassano | |
Italy | Research Site | Roma | |
Italy | Research Site | S.Andrea Delle Fratte | |
Mexico | Research Site | Aguascalientes | |
Mexico | Research Site | Mexico | |
Mexico | Research Site | Puebla | |
Philippines | Research Site | Cebu City | |
Philippines | Research Site | Manila | |
Philippines | Research Site | Pasay City | |
Philippines | Research Site | Quezon City | |
Portugal | Research Site | Lisboa | |
Portugal | Research Site | Santa Maria da Feira | |
Portugal | Research Site | Setúbal | |
South Africa | Research Site | Cape Town | |
South Africa | Research Site | Durban | |
South Africa | Research Site | Johannesburg | |
South Africa | Research Site | Port Elizabeth | |
South Africa | Research Site | Pretoria | |
Spain | Research Site | A Coruña | |
Spain | Research Site | Lugo | |
Spain | Research Site | Majadahonda | |
Spain | Research Site | Málaga | |
Spain | Research Site | Mataró(Barcelona) | |
Spain | Research Site | Orense | |
Spain | Research Site | Santiago De Compostela(A Coru | |
Spain | Research Site | Vigo(Pontevedra) | |
Sweden | Research Site | Lund | |
Sweden | Research Site | Sundsvall | |
Sweden | Research Site | Umeå | |
Sweden | Research Site | Uppsala | |
Sweden | Research Site | Västerås | |
Taiwan | Research Site | Taipei | |
United Kingdom | Research Site | Birmingham | |
United Kingdom | Research Site | Edinburgh | |
United Kingdom | Research Site | Leeds | |
United Kingdom | Research Site | Manchester | |
United Kingdom | Research Site | Wolverhampton | |
United States | Research Site | Austin | Texas |
United States | Research Site | Baltimore | Maryland |
United States | Research Site | Boston | Massachusetts |
United States | Research Site | Casa Grande | Arizona |
United States | Research Site | Chandler | Arizona |
United States | Research Site | Cincinnati | Ohio |
United States | Research Site | Farmington | Connecticut |
United States | Research Site | Gainesville | Georgia |
United States | Research Site | Hilton Head Island | South Carolina |
United States | Research Site | Middletown | Ohio |
United States | Research Site | Mineola | New York |
United States | Research Site | Mount Sterling | Kentucky |
United States | Research Site | Orlando | Florida |
United States | Research Site | Portland | Maine |
United States | Research Site | Rochester | New York |
United States | Research Site | Rockville | Maryland |
United States | Research Site | Saint Louis | Missouri |
United States | Research Site | Salt Lake City | Utah |
United States | Research Site | Sioux City | Iowa |
United States | Research Site | Skokie | Illinois |
United States | Research Site | Stamford | Connecticut |
United States | Research Site | Washington | District of Columbia |
United States | Research Site | Winston-Salem | North Carolina |
Venezuela | Research Site | Caracas | |
Venezuela | Research Site | Valencia |
Lead Sponsor | Collaborator |
---|---|
Genzyme, a Sanofi Company |
United States, Venezuela, Argentina, Australia, Belgium, Colombia, France, Germany, Greece, Hong Kong, India, Israel, Italy, Mexico, Philippines, Portugal, South Africa, Spain, Sweden, Taiwan, United Kingdom,
de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, Vansteenkiste JF. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-Free Survival (PFS) in the Overall Population | Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment | RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomisation until objective progression | |
Primary | Progression-Free Survival (PFS) in the Female Population | Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment | RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomisation until objective progression | |
Secondary | Overall Survival (OS) | Overall survival is defined as the time from date of randomization until death. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie their status must be known at the censored date and should not be lost to follow up or unknown). | Time to death in months | |
Secondary | Objective Response Rate (ORR) | The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as defined by RECIST criteria. The categories for best objective response are CR, PR, stable disease (SD)>= 6 weeks, progressive disease (PD) or NE. |
Each patient was assessed for objective response from the sequence of RECIST scan data up to data cut off. RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomisation until objective progression | |
Secondary | Disease Control Rate (DCR) | Disease control rate is defined as the number of patients who achieved disease control at 6 weeks following randomisation. Disease control at 6 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) >= 6 weeks | RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomisation until objective progression | |
Secondary | Duration of Response (DoR) | Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment) | RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomisation until objective progression | |
Secondary | Time to Deterioration of Disease-related Symptoms (TDS) by Lung Cancer Symptom Scale (LCSS) Total Score | TDS is the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days. A deterioration in symptoms is defined as a single visit assessment of 'worsened' with no visit assessment of 'improved' within the next 21 days. The LCSS scale measures changes in symptoms associated with lung cancer. | LCSS questionnaires are to be administered every 3 weeks after randomisation | |
Secondary | Time to Deterioration of Disease-related Symptoms (TDS) by Average Symptom Burden Index (ASBI) Score | Time to deterioration is defined as the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days. A deterioration in symptoms is defined as a single visit assessment of 'worsened' with no visit assessment of 'improved' within the next 21 days. The ASBI is derived from 6 of LCSS's 9 items | ASBI is a score taken from the LCSS questionnaires which are to be administered every 3 weeks after randomisation | |
Secondary | Longitudinal Analysis of Lung Cancer Symptom Scale (LCSS) Total Score | The longitudinal data analysis will include all non-missing visit scores and the model will include only the first 12 weeks of data. LCSS total score is an average of all nine visual analogue patient scales from "none" (0 mm) to "as much as it could be" (100 mm) | LCSS questionnaires are to be administered every 3 weeks after randomisation | |
Secondary | Longitudinal Analysis of Average Symptom Burden Index (ASBI) Score | The longitudinal data analysis will include all non-missing visit scores and the model will include only the first 12 weeks of data. ASBI is an average of the six symptom visual analogue patient scales from "none" (0 mm) to "as much as it could be" (100 mm). | ASBI is a score taken from the Lung Cancer Symptom Scale (LCSS) questionnaires administered every 3 weeks after randomisation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|